<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848143</url>
  </required_header>
  <id_info>
    <org_study_id>45231</org_study_id>
    <secondary_id>IIT-10247</secondary_id>
    <nct_id>NCT03848143</nct_id>
  </id_info>
  <brief_title>Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain</brief_title>
  <official_title>Intraoral Administration of Onabotulinum Toxin A for Continuous Neuropathic Pain: a Single Subject Experimental Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isabel Moreno Hay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan Sales, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Onabotulinum toxin type A (BoNT-A) is a potent neurotoxin that has been reported to have an
      effect on afferent (sensory) neurons independent of its action on muscle tone and secretory
      glands at the periphery.In human studies, the use of BoNT-A has proven to reduce the severity
      and intensity of attacks in chronic tension type headaches and chronic neck pain. The PREEMPT
      study concluded that BoNT-A could be used as a preventive therapy in chronic migraine
      patients and FDA approval was obtained. According to the International Association for the
      Study of Pain (IASP), BoNT-A is recommended for the management of peripheral neuropathic pain
      with subcutaneous administration of 50-200 units (50-200U) to onabotulinum toxin A to the
      painful neuropathic area every 3 months as a third line of treatment. To our knowledge, there
      are no clinical trials published investigating the effect of intraoral administration of
      BoNT-A in continuous dentoalveolar neuropathic pain. The aim of this pilot study is to
      investigate the potential therapeutic effect of intraoral administration of BoNT-A in
      patients suffering from continuous neuropathic pain.

      HYPOTHESIS:

      There will be statistically significant differences in reported pain intensity after the
      intraoral administration of BOTOX® in patients suffering from chronic continuous
      dentoalveolar neuropathic pain.

      A single subject experiment will be conducted with 10 patients where 50 U of BonT-A will be
      injected into the painful dentoalveolar area. Eligible subjects will complete a pain diary
      indicating their pain intensity by means of a visual analog scale during one month to
      establish a baseline. After the first injection, subjects will continue to monitor the VAS
      daily for 3 months and the infiltration will be repeated a second time following the same
      protocol. Patient's response will be monitored with the daily pain diary.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single subject experimental design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>Over 7 months</time_frame>
    <description>Patient will record the pain intensity by means of a visual analogue scale (VAS, from 0-10 being 0 no pain and 10 the worst possible pain)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>BOTOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
Each patient will receive 50 U of onabotulinum toxin A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinum toxin A</intervention_name>
    <description>Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.</description>
    <arm_group_label>BOTOX</arm_group_label>
    <other_name>BOTOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of continuous dentoalveolar pain with clinically evident positive
             (hyperalgesia, allodynia) and/or negative (hypoaesthesia, hypoalgesia) signs of
             trigeminal nerve dysfunction and where other possible pain sources have been ruled
             out.

          -  Intractable pain to conventional oral and/or topical pharmacotherapy for neuropathic
             pain according to the recommendations published by NeuPSIG (Neuropathic Pain Special
             Interest Group) including anticonvulsants, SNRIs (serotonin and norepinephrine
             reuptake inhibitors) and/or tricyclic antidepressants.

          -  Subject consent to participate in the study.

        Exclusion Criteria:

          -  hypersensitive to any onabotulinum toxin preparation or any component in the
             formulation.

          -  systemic nerve or muscle disorders

          -  bleeding disorders

          -  dysphagia

          -  breathing problems

          -  pregnancy or breastfeeding

          -  previous treatment with botulinum toxin in the last 4 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey P Okeson, DMD</last_name>
    <role>Study Director</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Moreno Hay, DDS PhD</last_name>
    <phone>8593233440</phone>
    <email>imo226@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orofacial Pain Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel M Hay, DDS PhD</last_name>
      <phone>859-323-8873</phone>
      <phone_ext>9</phone_ext>
      <email>imo226@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dolly JO, O'Connell MA. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol. 2012 Feb;12(1):100-8. doi: 10.1016/j.coph.2011.11.001. Epub 2011 Dec 19. Review.</citation>
    <PMID>22188874</PMID>
  </reference>
  <reference>
    <citation>Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33.</citation>
    <PMID>14715398</PMID>
  </reference>
  <reference>
    <citation>Luvisetto S, Marinelli S, Lucchetti F, Marchi F, Cobianchi S, Rossetto O, Montecucco C, Pavone F. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. 2006 Apr 12;1082(1):124-31. Epub 2006 Mar 9.</citation>
    <PMID>16524562</PMID>
  </reference>
  <reference>
    <citation>Bach-Rojecky L, Lacković Z. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J. 2005 Apr;46(2):201-8.</citation>
    <PMID>15849840</PMID>
  </reference>
  <reference>
    <citation>Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, Mezzaroma E, Caruso M, Straface E, Przewlocka B, Pavone F. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience. 2010 Nov 24;171(1):316-28. doi: 10.1016/j.neuroscience.2010.08.067. Epub 2010 Sep 6.</citation>
    <PMID>20826198</PMID>
  </reference>
  <reference>
    <citation>Bach-Rojecky L, Relja M, Lacković Z. Botulinum toxin type A in experimental neuropathic pain. J Neural Transm (Vienna). 2005 Feb;112(2):215-9.</citation>
    <PMID>15657640</PMID>
  </reference>
  <reference>
    <citation>Park HJ, Lee Y, Lee J, Park C, Moon DE. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth. 2006 May;53(5):470-7.</citation>
    <PMID>16636031</PMID>
  </reference>
  <reference>
    <citation>Bach-Rojecky L, Salković-Petrisić M, Lacković Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol. 2010 May 10;633(1-3):10-4. doi: 10.1016/j.ejphar.2010.01.020. Epub 2010 Feb 1.</citation>
    <PMID>20123097</PMID>
  </reference>
  <reference>
    <citation>Filipović B, Bach-Rojecky L, Lacković Z. Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat. Fundam Clin Pharmacol. 2010 Feb;24(1):43-5. doi: 10.1111/j.1472-8206.2009.00767.x. Epub 2009 Aug 14.</citation>
    <PMID>19682079</PMID>
  </reference>
  <reference>
    <citation>Relja M, Telarović S. Botulinum toxin in tension-type headache. J Neurol. 2004 Feb;251 Suppl 1:I12-4.</citation>
    <PMID>14991337</PMID>
  </reference>
  <reference>
    <citation>Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study. Pain Med. 2009 Sep;10(6):1012-7. doi: 10.1111/j.1526-4637.2009.00658.x. Epub 2009 Jul 6.</citation>
    <PMID>19594841</PMID>
  </reference>
  <reference>
    <citation>Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7.</citation>
    <PMID>20487038</PMID>
  </reference>
  <reference>
    <citation>Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi: 10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7. Review.</citation>
    <PMID>25575710</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Isabel Moreno Hay</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

